Author expects RGNX to rise 50% by end of year due to upcoming PDUFA catalysts and positive long-term data.
RGNX — LONG Author expects REGENXBIO shares to rise 50% by end of year. The Hunter syndrome PDUFA date is February 8, and the FDA delay was due to new longer-term data that the author says results were great. Approval would include a priority review voucher, which the author notes last sold for $160 million. Additionally, pivotal DMD results are expected in Q1 with a filing in mid-2026.
I am expecting share price to be up 50% by eoy.
This Reddit post, published January 01, 2026, features u/fbksminer discussing RGNX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/fbksminer · Tickers: RGNX